Home LiteratureArticle Details
PMID: 23749739 Published · ppublish English Journal Article

Immunosuppressive mechanisms of regulatory dendritic cells in cancer.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society ·Vol. 6 ·No. 2 ·2013-08-00 ·Pages 159-67

Shurin GV, Ma Y, Shurin MR

Abstract

Three major functional subsets of dendritic cells (DCs) have been described in the tumor microenvironment in patients with cancer and tumor-bearing animals: (i) conventional DCs with intact antigen-presenting capabilities, (ii) functionally defective DCs with decreased motility and low ability to uptake, process and present antigens or produce cytokines and (iii) regulatory DCs with high capacity to suppress T cell proliferation, induce differentiation of regulatory T cells or support immune tolerance. Phenotypic characteristics of regulatory DCs (regDCs), as well as the mechanisms of T cell inhibition, vary in different experimental conditions and environments, suggesting high level of their plasticity and probably different origin. Although new data demonstrate that regDCs may play an important role at early stages of tumor development, functional differences and clinical significance of emergence of different myeloid regulatory cells (MDSCs, regDCs, M2 macrophages, N2 neutrophils, mast cells) in cancer remain to be determined.

Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Shurin Galina V
Division of Experimental Pathology, Department of Pathology, University of Pittsburgh Medical Center, Scaife Hall S733 3550 Terrace Street, Pittsburgh, PA, 15261, USA, shuringv@upmc.edu.
Ma Yang
Shurin Michael R
References (103)
103 references, click to expand
  1. Adrenomedullin, a neuropeptide with immunoregulatory properties induces semi-mature tolerogenic dendritic cells.
    Immunology. 2012 Jun;136(2):252-64 PMID: 22348691
  2. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation.
    J Immunol. 2000 Apr 1;164(7):3596-9 PMID: 10725715
  3. Vitamin D3 induces IDO+ tolerogenic DCs and enhances Treg, reducing the severity of EAE.
    CNS Neurosci Ther. 2013 Apr;19(4):269-77 PMID: 23521914
  4. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes.
    Eur J Immunol. 1994 Apr;24(4):1007-9 PMID: 7512027
  5. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.
    Immunol Invest. 2012;41(6-7):765-97 PMID: 23017145
  6. Recruitment and differentiation of conventional dendritic cell precursors in tumors.
    J Immunol. 2010 Feb 1;184(3):1261-7 PMID: 20026742
  7. The polarization of immune cells in the tumour environment by TGFbeta.
    Nat Rev Immunol. 2010 Aug;10(8):554-67 PMID: 20616810
  8. Splenic stroma-educated regulatory dendritic cells induce apoptosis of activated CD4 T cells via Fas ligand-enhanced IFN-γ and nitric oxide.
    J Immunol. 2012 Feb 1;188(3):1168-77 PMID: 22205032
  9. Neuropeptide signaling activates dendritic cell-mediated type 1 immune responses through neurokinin-2 receptor.
    J Immunol. 2012 May 1;188(9):4200-8 PMID: 22474018
  10. Dendritic cells in rheumatoid arthritis: Which subset should be used as a tool to induce tolerance?
    Hum Immunol. 2009 May;70(5):321-4 PMID: 19236901
  11. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity.
    J Immunol. 2011 Mar 15;186(6):3346-55 PMID: 21317386
  12. Role of regulatory dendritic cells in allergy and asthma.
    Curr Allergy Asthma Rep. 2005 Jan;5(1):56-61 PMID: 15659264
  13. Tolerogenic dendritic cells transferring hyporesponsiveness and synergizing T regulatory cells in transplant tolerance.
    Int Immunol. 2008 Feb;20(2):285-93 PMID: 18182381
  14. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma.
    Int J Cancer. 1997 Nov 4;73(3):309-16 PMID: 9359474
  15. Regulatory dendritic cells in the tumor immunoenvironment.
    Cancer Immunol Immunother. 2012 Feb;61(2):223-230 PMID: 22065047
  16. A gene signature of inhibitory MHC receptors identifies a BDCA3(+) subset of IL-10-induced dendritic cells with reduced allostimulatory capacity in vitro.
    Eur J Immunol. 2004 Oct;34(10):2800-11 PMID: 15368296
  17. Indoleamine 2,3-dioxygenase in immune suppression and cancer.
    Curr Cancer Drug Targets. 2007 Feb;7(1):31-40 PMID: 17305476
  18. Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells.
    J Neuroimmunol. 2003 Dec;145(1-2):55-67 PMID: 14644031
  19. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.
    Cancer Immunol Immunother. 2012 Feb;61(2):289-293 PMID: 22237887
  20. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.
    Cancer Cell. 2005 Nov;8(5):369-80 PMID: 16286245
  21. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.
    J Immunol. 2002 Jan 15;168(2):689-95 PMID: 11777962
  22. Complexities of TGF-β targeted cancer therapy.
    Int J Biol Sci. 2012;8(7):964-78 PMID: 22811618
  23. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
    Nat Med. 2005 Mar;11(3):312-9 PMID: 15711557
  24. α-MSH-stimulated tolerogenic dendritic cells induce functional regulatory T cells and ameliorate ongoing skin inflammation.
    J Invest Dermatol. 2012 Jul;132(7):1814-24 PMID: 22418871
  25. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner.
    Clin Cancer Res. 2011 Dec 1;17(23):7230-9 PMID: 21994414
  26. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses.
    J Immunol. 2002 Apr 15;168(8):3771-6 PMID: 11937528
  27. Dendritic cells as immune regulators: the mouse model.
    J Cell Mol Med. 2008 Oct;12(5B):1909-14 PMID: 18544050
  28. Ambivalent effects of dendritic cells displaying prostaglandin E2-induced indoleamine 2,3-dioxygenase.
    Eur J Immunol. 2012 May;42(5):1117-28 PMID: 22539287
  29. Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8⁺ T cell priming.
    PLoS One. 2012;7(12):e51845 PMID: 23272178
  30. Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1.
    Eur J Immunol. 2003 Jul;33(7):1988-97 PMID: 12884865
  31. Functions of TGF-β-exposed plasmacytoid dendritic cells.
    Crit Rev Immunol. 2012;32(6):529-53 PMID: 23428227
  32. Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression.
    Eur J Immunol. 1994 Jun;24(6):1293-300 PMID: 8206089
  33. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity.
    Clin Exp Immunol. 2006 Nov;146(2):189-96 PMID: 17034569
  34. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits.
    Science. 1994 Nov 11;266(5187):1045-7 PMID: 7973659
  35. Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells.
    J Leukoc Biol. 2008 Jul;84(1):124-33 PMID: 18430785
  36. Melanocortin 1 receptor regulates melanoma cell migration by controlling syndecan-2 expression.
    J Biol Chem. 2012 Jun 1;287(23):19326-35 PMID: 22493442
  37. Tolerogenic dendritic cells in the control of autoimmune neuroinflammation: an emerging role of protein-glycan interactions.
    Neuroimmunomodulation. 2010;17(3):157-60 PMID: 20134191
  38. Dendritic cells in networks of immunological tolerance.
    Tissue Antigens. 2011 Feb;77(2):89-99 PMID: 21214520
  39. TGF-beta: a master switch in tumor immunity.
    Curr Pharm Des. 2012;18(27):4126-34 PMID: 22630082
  40. Induction of tolerance by IL-10-treated dendritic cells.
    J Immunol. 1997 Nov 15;159(10):4772-80 PMID: 9366401
  41. FOXO3: A master switch for regulating tolerance and immunity in dendritic cells.
    Oncoimmunology. 2012 Mar 1;1(2):252-254 PMID: 22720261
  42. TGF-β of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation.
    Oncol Rep. 2012 Aug;28(2):615-21 PMID: 22614805
  43. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.
    J Exp Med. 2005 Oct 3;202(7):919-29 PMID: 16186184
  44. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
    Nat Rev Cancer. 2005 Apr;5(4):263-74 PMID: 15776005
  45. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells.
    Nat Immunol. 2004 Nov;5(11):1124-33 PMID: 15475957
  46. CCL18 differentiates dendritic cells in tolerogenic cells able to prime regulatory T cells in healthy subjects.
    Blood. 2011 Sep 29;118(13):3549-58 PMID: 21803856
  47. Neurotensin downregulates the pro-inflammatory properties of skin dendritic cells and increases epidermal growth factor expression.
    Biochim Biophys Acta. 2011 Oct;1813(10):1863-71 PMID: 21767580
  48. Dendritic cells in the cancer microenvironment.
    J Cancer. 2013;4(1):36-44 PMID: 23386903
  49. Galectin-1 and -3 gene silencing in immature and mature dendritic cells enhances T cell activation and interferon-γ production.
    J Leukoc Biol. 2012 Mar;91(3):461-7 PMID: 22167721
  50. Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines.
    Curr Drug Metab. 2007 Apr;8(3):237-44 PMID: 17430112
  51. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
    J Immunol. 2009 May 15;182(10):6207-16 PMID: 19414774
  52. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders.
    Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2159-64 PMID: 20080669
  53. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3.
    J Thorac Oncol. 2011 Jul;6(7):1162-8 PMID: 21597388
  54. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.
    J Exp Med. 1991 Oct 1;174(4):915-24 PMID: 1655948
  55. PD-1 and its ligands in T-cell immunity.
    Curr Opin Immunol. 2007 Jun;19(3):309-14 PMID: 17433872
  56. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells.
    Transpl Immunol. 2003 Jul-Sep;11(3-4):245-58 PMID: 12967778
  57. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1.
    J Allergy Clin Immunol. 2007 Jul;120(1):76-83 PMID: 17531298
  58. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development.
    J Exp Med. 2007 May 14;204(5):1037-47 PMID: 17438063
  59. Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent pathways.
    J Immunol. 2008 Sep 1;181(5):3089-98 PMID: 18713979
  60. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.
    J Clin Invest. 2004 Jul;114(2):280-90 PMID: 15254595
  61. Macrophages in tumor microenvironments and the progression of tumors.
    Clin Dev Immunol. 2012;2012:948098 PMID: 22778768
  62. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice.
    J Immunol. 1996 Jan 1;156(1):73-8 PMID: 8598496
  63. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding.
    FASEB J. 2000 Sep;14(12):1666-8 PMID: 10973911
  64. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
    Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10691-6 PMID: 15249675
  65. IL-10 inhibits cytokine production by activated macrophages.
    J Immunol. 1991 Dec 1;147(11):3815-22 PMID: 1940369
  66. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells.
    J Immunol. 2009 Mar 1;182(5):2795-807 PMID: 19234174
  67. Tumor-driven evolution of immunosuppressive networks during malignant progression.
    Cancer Res. 2006 Jun 1;66(11):5527-36 PMID: 16740684
  68. Immunostimulatory conventional dendritic cells evolve into regulatory macrophage-like cells.
    Blood. 2012 May 24;119(21):4919-27 PMID: 22490680
  69. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer.
    J Immunol. 2011 Jun 15;186(12):6905-13 PMID: 21551365
  70. Tolerogenic dendritic cells in cancer, transplantation, and autoimmune diseases.
    Hum Immunol. 2009 May;70(5):277-80 PMID: 19275919
  71. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression.
    Mol Immunol. 2008 Dec;46(2):258-68 PMID: 18824264
  72. Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection.
    J Clin Invest. 2006 Dec;116(12):3160-70 PMID: 17111046
  73. Immunosuppressive strategies that are mediated by tumor cells.
    Annu Rev Immunol. 2007;25:267-96 PMID: 17134371
  74. Tumor associated regulatory dendritic cells.
    Semin Cancer Biol. 2012 Aug;22(4):298-306 PMID: 22414911
  75. CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease.
    Nat Immunol. 2008 Nov;9(11):1253-60 PMID: 18836452
  76. Tolerogenic dendritic cells induce CD4+CD25hiFoxp3+ regulatory T cell differentiation from CD4+CD25-/loFoxp3- effector T cells.
    J Immunol. 2010 Nov 1;185(9):5003-10 PMID: 20870943
  77. Tolerance, DCs and tryptophan: much ado about IDO.
    Trends Immunol. 2003 May;24(5):242-8 PMID: 12738417
  78. Tolerogenic dendritic cells in health and disease: friend and foe!
    Eur J Dermatol. 2007 Nov-Dec;17(6):476-91 PMID: 17951127
  79. Neuropeptides control the dynamic behavior of airway mucosal dendritic cells.
    PLoS One. 2012;7(9):e45951 PMID: 23049899
  80. T cell apoptosis by kynurenines.
    Adv Exp Med Biol. 2003;527:183-90 PMID: 15206731
  81. Central role of extracellular signal-regulated kinase and Toll-like receptor 4 in IL-10 production in regulatory dendritic cells induced by Trypanosoma cruzi.
    Mol Immunol. 2010 Jul;47(11-12):1981-8 PMID: 20537708
  82. TGF-beta as a T cell regulator in colitis and colon cancer.
    Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):97-106 PMID: 16298544
  83. IDO expression by dendritic cells: tolerance and tryptophan catabolism.
    Nat Rev Immunol. 2004 Oct;4(10):762-74 PMID: 15459668
  84. Regulation of expression and function of IDO in human dendritic cells.
    Curr Med Chem. 2011;18(15):2222-33 PMID: 21517757
  85. Programmed death-1 signaling is essential for the skin allograft protection by alternatively activated dendritic cell infusion in mice.
    Transplantation. 2009 Oct 15;88(7):864-73 PMID: 19935456
  86. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.
    J Immunol. 2004 Jan 15;172(2):989-99 PMID: 14707072
  87. Murine myeloid dendritic cells that phagocytose apoptotic T cells inhibit the immune response via NO.
    PLoS One. 2012;7(11):e49378 PMID: 23166651
  88. Intestinal CD103+ dendritic cells: master regulators of tolerance?
    Trends Immunol. 2011 Sep;32(9):412-9 PMID: 21816673
  89. Naturally occurring CD1c+ human regulatory dendritic cells: immunoregulators that are expanded in response to E. coli infection.
    Eur J Immunol. 2012 Jun;42(6):1388-92 PMID: 22678895
  90. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.
    Cancer Res. 2009 Apr 1;69(7):3086-94 PMID: 19293186
  91. Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node.
    J Immunol. 2006 May 1;176(9):5637-43 PMID: 16622033
  92. Arginase: an emerging key player in the mammalian immune system.
    Br J Pharmacol. 2009 Oct;158(3):638-51 PMID: 19764983
  93. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction--a comparative study of human clinical-applicable DC.
    Clin Immunol. 2012 Mar;142(3):332-42 PMID: 22225835
  94. IL-10 inhibits human T cell proliferation and IL-2 production.
    J Immunol. 1992 Feb 15;148(4):1143-8 PMID: 1737931
  95. Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system.
    Cancer Immunol Immunother. 2005 Sep;54(9):898-906 PMID: 15776284
  96. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells.
    Front Immunol. 2013 Apr 03;4:82 PMID: 23565116
  97. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators.
    Semin Cancer Biol. 2006 Feb;16(1):38-52 PMID: 16139507
  98. Tryptophan and the immune response.
    Immunol Cell Biol. 2003 Aug;81(4):247-65 PMID: 12848846
  99. Regulatory dendritic cells: new targets for cancer immunotherapy.
    Cancer Biol Ther. 2011 Jun 1;11(11):988-92 PMID: 21474998
  100. Transforming growth factor-β1 modulates lipopolysaccharide-induced cytokine/chemokine production and inhibits nuclear factor-κB, extracellular signal-regulated kinases and p38 activation in dendritic cells in mice.
    Transplant Proc. 2011 Jun;43(5):2049-52 PMID: 21693323
  101. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
    Immunol Rev. 2008 Apr;222:162-79 PMID: 18364001
  102. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
    Curr Opin Immunol. 2012 Apr;24(2):207-12 PMID: 22236695
  103. The characteristics and immunoregulatory functions of regulatory dendritic cells induced by mesenchymal stem cells derived from bone marrow of patient with chronic myeloid leukaemia.
    Eur J Cancer. 2012 Aug;48(12):1884-95 PMID: 22129888
Article Info
Journal
Cancer microenvironment : official journal of the International Cancer Microenvironment Society
Abbr.
Cancer Microenviron
ISSN
1875-2292
DOI
10.1007/s12307-013-0133-3
Email
shuringv@upmc.edu
Published
2013-08-00
Epub
2013-00-09
Pages
159-67
Language
English
Region
Netherlands
NLM ID
101322634
PMCID
PMC3717058
Grants
NCI NIH HHS · R01 CA154369 · United States
External Links
PubMed source DOI: 10.1007/s12307-013-0133-3 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2